Current stock page

Catalysts

SRRK Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

SRRKScholar Rock Holding Corporation

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 6/10
$43.21+$0.05 (+0.10%)

Latest quote

  • Momentum
    54
  • Value
    —
  • Quality
    14
  • Risk resilience
    52
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 2, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 39/100

Momentum 54/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 30.46%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 54/100AIQ Edge 6/10 Above Peers
Beat rate
38%
3 of 8 reported periods
Average surprise
-7.4%
Across covered historical reports
Latest result
+4.4%
Nov 10, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 10, 2026—-$0.85-$0.81+4.4%$303.93K$600K
Aug 6, 2026—-$0.84-$0.84+0.1%$70K—
May 7, 2026—-$0.82-$0.83-1.2%$5M—
Mar 3, 2026—-$0.88-$0.88+0.3%$1.83M—
Nov 14, 2025—-$0.84-$0.90-7.8%$50K—
Aug 6, 2025—-$0.66-$0.98-48.5%$55.56K—
May 14, 2025—-$0.63-$0.67-6.3%——
Feb 27, 2025—-$0.60-$0.60+0.0%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
17
Buy
2
Hold
12-month analyst target
$71.30
+65.03% versus current price
Based on 19 analyst observations. Targets are estimates, not predictions.
Low target
$58.00
+34.24% vs latest price
Average target
$71.30
+65.03% vs latest price
High target
$84.00
+94.42% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 2, 2027

Next known earnings or reporting date.

EPS estimate-$0.42

Current analyst expectation for the upcoming report.

Revenue estimate$4.33M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score54

Where event reaction would show up first.

AIQ score39/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
19
Average target
$71.30
Target upside
65.03%
Target range
$58.00 - $84.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
1
zacks.com · Nov 10, 2026

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates

Scholar Rock (SRRK) delivered earnings and revenue surprises of +6.90% and +119.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

gurufocus.com · Nov 9, 2026

Scholar Rock (SRRK) Prepares to Report Q3 Earnings Amid High Price-to-Sales Valuation

On November 09, 2026, Scholar Rock Holding Corp (NASDAQ: SRRK) is scheduled to release its third-quarter earnings before the market opens on November 10. Invest

gurufocus.com · Sep 25, 2026

Scholar Rock Holding Corp (SRRK) Gains Wedbush Spotlight Amid Valuation and Insider Activity Insights

On September 25, 2026, Scholar Rock Holding Corp (NASDAQ: SRRK) was named to Wedbush's Best Ideas List, spotlighting its potential for a robust commercial ramp

insidermonkey.com · Sep 17, 2026

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently...

seekingalpha.com · Sep 14, 2026

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment September 14, 2026 8:00 AM EDTCompany...

Open full news and sentiment

SRRK Catalysts FAQ

What are the next catalysts for SRRK stock?

SRRK's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move SRRK stock?

Upcoming events that could move SRRK include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could SRRK's next earnings report affect the stock?

SRRK's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive SRRK stock higher?

SRRK could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt SRRK stock?

SRRK could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.